Ascentage Pharma Group International furnishes SEC filings as a foreign private issuer reporting under Form 6-K and indicating annual reporting on Form 20-F. The filings document press releases and Hong Kong Stock Exchange announcements for annual results, oncology pipeline updates, clinical and preclinical presentation materials, and changes in corporate administration.
The company’s filing record also includes Hong Kong annual report and environmental, social and governance materials, annual general meeting notices, proxy forms, director re-election matters, general mandates to issue or repurchase shares, and supplemental equity-incentive grant proposals under its RSU and post-IPO share option schemes.
Ascentage Pharma Group International filed a Form S-8 to register the issuance of an additional 5,800,000 ordinary shares of common stock, par value US$0.0001 per share, under its Amended 2022 Restricted Share Unit Scheme. This expands the pool of shares available for equity awards to employees and other eligible participants.
The company had previously registered 5,272,695 ordinary shares for the original 2022 Restricted Share Unit Scheme on a prior Form S-8. The new filing incorporates that earlier registration by reference and includes customary exhibits such as legal opinions, auditor consents and the amended RSU scheme document. The registration statement is signed on behalf of the company by its Chief Executive Officer, Dajun Yang.
Ascentage Pharma Group International filed a Post-Effective Amendment No. 1 to its Form S-8 to adjust how previously registered equity is allocated between employee incentive plans. The company is reallocating 5,800,000 Ordinary Shares from its Post-IPO Option Scheme, as amended, to its 2022 Restricted Share Unit Scheme, as amended. This amendment deregisters the Ordinary Shares that were registered under the earlier Form S-8 for use in the Post-IPO Option Scheme but will not be used for awards under that option plan. At the same time, the company is filing a new Form S-8 to register Ordinary Shares now available for offer or sale under the 2022 RSU Scheme.
Ascentage Pharma Group International furnished a Form 6-K highlighting its 2025 interim results disclosures and governance updates. The company attached a press release on unaudited six‑month financial results and a Hong Kong Stock Exchange announcement as exhibits.
The filing also explains a previously closed offshore placement and top‑up subscription in which an affiliate of the CEO sold 22 million ordinary shares and received 22 million new ordinary shares at HKD68.60 per share, providing the company with approximately HKD1,492 million (about US$190.1 million) in net proceeds. In connection with this and a prior top‑up placement, the board approved a new form of indemnification agreement extending protections to certain affiliates of directors and officers and authorized payment of up to US$600,000 in interest to those indemnified persons whose share loans facilitated the placements.
Ascentage Pharma Group International submitted a Form 6-K noting that it has furnished two communications about a key clinical milestone for its oncology candidate lisaftoclax. On August 17, 2025, the company issued a press release announcing that a global registrational Phase III trial of lisaftoclax for the first-line treatment of patients with myelodysplastic syndrome was cleared by the US FDA and the European Medicines Agency (EMA). On August 18, 2025, it also published a voluntary announcement on the Hong Kong Stock Exchange describing a global registrational Phase III study of lisaftoclax for first-line treatment of higher-risk myelodysplastic syndrome (HR-MDS) cleared by the FDA and EMA.
Ascentage Pharma Group International submitted a Form 6-K noting that it has furnished a Hong Kong Stock Exchange announcement titled “Notice of Board Meeting.” The announcement, dated August 8, 2025, is attached as Exhibit 99.1. The report is signed by Chief Executive Officer Dajun Yang.